Bonus Content

Watch Our Prerecorded Deep Dive Discussions

Driving the Industry Applications of Tissue-on-Chip Systems

 

  • Sharing industry progress behind producing robust, reliable and replicable
    results in microfluidic system
    Standardizing tissue composition, and physiologic and pharmacologic responses to well-known agents to assess physiological relevancy
  • Evaluating the steps to increase wide-spread adoption and commercialization of organ-on-chip systems
  • Balancing high-throughput requirements with physiological  relevancy
  • Importance of 3D tissue models in increasing translatability and predictiveness of efficacy and toxicity studies of potential drug candidates
  • Actionable insights & lessons learnt from industry representatives.

Facilitated by:

Joep Beumer
norman peterson jpg
graham marsh biogen jpg

Joep Buemer 
PhD Student
Hubrecht Insititute

Norman Peterson
Independent Consultant
Biopharmaceutical Development and Life Sciences

Graham Marsh
Scientist
Biogen

Multi-Organ-on-Chip Systems: Benefits, Challenges, Opportunities

 

  • Current limitations of 3D tissue models and navigating the challenges around developing multi-tissue and multi-organ systems
  • Interconnecting circulating mediums in multi-tissue devices
  • Assessing physiological relevance in multi-organ systems
  • Observing complex responses, such as how the response of one tissue type impacts another
  • Incorporating immune system response into 3D tissue models
  • When to use multi-organ-on-chip systems over less complex 3D tissue models in the continuum of testing
  • Development, validation and commercialisation of multi-organon-chip systems

Facilitated by:

andreas stahl
Ashutosh Agarwal
james hickman

Andreas Stahl
Professor, Dept. of Nutritional Sciences & Toxicology
UC Berkeley

Ashutosh Agarwal
Assistant Professor
University of Miami

James J. Hickman
Professor, NanoScience Technology Center
University Central Florida